预约演示
更新于：2025-04-15
Epinastine Hydrochloride
盐酸依匹斯汀
更新于：2025-04-15
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS号108929-04-0 |
关联
50
项与 盐酸依匹斯汀 相关的临床试验CTR20243732
盐酸依匹斯汀片在健康受试者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
CTR20234212
0.1%STN1011403滴眼液治疗过敏性结膜炎的多中心随机评价者盲态阳性对照试验
CTR20231572
0.05%盐酸依匹斯汀滴眼液治疗中国过敏性结膜炎患者的有效性和安全性的随机、双盲、阳性药平行对照、多中心临床研究
100 项与 盐酸依匹斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的专利（医药）
登录后查看更多信息
306
项与 盐酸依匹斯汀 相关的文献（医药）2025-04-01CHEMOSPHERE
Abating a micropollutant epinastine by UV-based advanced oxidation processes: Comparison for UV/hydrogen peroxide, UV/persulfate, and UV/chlorine, impacts of bromide contents, and formation of DBPs during post-chlorination
Article
作者: Murata, Yuichiro ; Sakai, Hiroshi
Anthropogenic organic compounds, such as pharmaceuticals and personal care products, contaminate water, posing toxicological risks caused by either their parent compounds or transformation products. This study compares ultraviolet (UV)-based advanced oxidation processes (UV/hydrogen peroxide, UV/persulfate, and UV/chlorine) for the abatement of an antihistamine drug epinastine. UV light at 254 nm was irradiated upon solutions containing 10 μM epinastine and 100 μM oxidant. UV/chlorine degraded epinastine most effectively at pH 6.0-8.0; considerable contributions by reactive chlorine species and hydroxyl radicals were quantified using probe compounds. Furthermore, the degradation efficiency of the UV/chlorine treatment persisted with a halved chlorine dosage. Additionally, the types and concentrations of disinfection byproducts (DBPs) produced during UV/chlorine treatment with or without post-chlorination varied depending on the concentrations of chlorine or bromide. By comparing estimated DBP formations at a constant degradation rate of epinastine, UV/chlorine formed smaller concentrations of DBPs. Consequently, this study experimentally revealed that UV/chlorine is superior to UV/hydrogen peroxide and UV/persulfate for degrading epinastine at the possible pH and bromide content in the environment and controlling toxicological risks caused by disinfection DBPs formation by optimising chlorine dosage and UV fluence.
2025-02-28Cureus Journal of Medical Science
Successful Transition From Topical Ophthalmic Drops to Cream Formulation in the Management of Mild Allergic Conjunctivitis: A Case Report
Article
作者: Nishio, Mai ; Fujishima, Hiroshi ; Shimizu, Eisuke ; Fukagawa, Kazumi ; Asai, Kazuki
This case report highlights the successful transition from epinastine eye drops to a novel epinastine eyelid cream in managing mild allergic conjunctivitis. A 33-year-old Japanese female with mild allergic conjunctivitis, previously managed with 0.1% epinastine hydrochloride eye drops, requested an alternative formulation due to daily contact lens wear. Treatment was changed to a once-daily application of 0.5% epinastine hydrochloride eyelid cream. Clinical assessment and symptom evaluation were performed at baseline and after 28 days using slit-lamp examination and the Japanese Allergic Conjunctival Disease Quality of Life Questionnaire. Following the transition, the patient's clinical signs (mild conjunctival hyperemia and moderate papillae) and subjective symptoms (itching and mild discomfort) remained stable. Slit-lamp examination showed no corneal or limbal pathology, and tear fluid immunoglobulin E (IgE) testing remained positive, consistent with mild allergic conjunctivitis. No adverse effects or cutaneous reactions were observed. This case suggests that epinastine eyelid cream may serve as an effective once-daily alternative to conventional eye drops in mild allergic conjunctivitis. While this represents the first documented successful transition between delivery methods, larger clinical trials are warranted to confirm these findings and explore applications across various presentations and severities of allergic ocular disease.
2025-01-01Forensic Toxicology
Effects of natural environments on drug contents in nails: comparison of drug residual rates between nails and hair to determine the drug-use history of corpses in unnatural death cases using micro-segmental analysis
Article
作者: Kanamori, Tatsuyuki ; Okada, Yuki ; Yamamuro, Tadashi ; Tsujikawa, Kenji ; Iwata, Yuko T ; Miyaguchi, Hajime ; Segawa, Hiroki ; Kuwayama, Kenji
PURPOSE:
We previously developed evaluation methods using micro-segmental analysis (MSA) to examine the effects of external environments on drug content in hair and nails. In this study, the effects of the natural environmental factors (water, temperature, humidity, light, and soil) on drug contents in nails were examined and compared with our previous experimental data on hair.
METHODS:
Four hay-fever medicines were used as model drugs (fexofenadine, epinastine, cetirizine, and desloratadine) to evaluate drug stability in the nails. Reference nails containing the four medicines were collected from patients with hay fever who ingested the medicines daily for four months. The nails were exposed to various natural environments for up to four months.
RESULTS:
The effects of temperature, humidity, and light on drug contents in the nails were comparatively small. Soil significantly decomposed the nail surfaces and decreased the drug content of the nails (up to 17 %). Water also decreased the drug content (up to 12 %), although no apparent changes in nail surfaces were observed.
CONCLUSIONS:
In comparison with hair data obtained under the same environmental conditions, light affected drugs in the hair rather than in nails, whereas water and soil greatly affected drugs in the nails rather than in hair. Although the disposition of drugs incorporated in the tissues differed between nails and hair, the analytes were detected in nails and hair strands left in severe natural environments. MSA could be useful for estimating drug-use histories and personal profiles using the nails and hair of a corpse.
100 项与 盐酸依匹斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 日本 | 2013-09-20 | |
| 季节性过敏性结膜炎 | 奥地利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 比利时 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 捷克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 丹麦 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 法国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 德国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 希腊 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 匈牙利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 爱尔兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 意大利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 卢森堡 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 荷兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 波兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 葡萄牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 斯洛伐克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 西班牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 瑞典 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 英国 | 2003-03-04 | |
| 银屑病 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性鼻炎 | 临床3期 | - | 2007-12-18 | |
| 特应性皮炎 | 临床3期 | - | 2001-06-01 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 87 | Epinastine (DE-114) (Epinastine (DE-114) Ophthalmic Solution) | 選餘醖選壓壓衊壓選願(範鏇鬱顧網壓願壓範觸) = 蓋壓鑰廠淵鹹襯獵積築 夢壓齋糧遞窪鹽膚鹽觸 (夢鑰觸窪壓鬱顧網膚鏇, 0.1) 更多 | - | 2014-11-05 | ||
Placebo (Placebo Ophthalmic Solution) | 選餘醖選壓壓衊壓選願(範鏇鬱顧網壓願壓範觸) = 糧廠選製築醖襯積繭範 夢壓齋糧遞窪鹽膚鹽觸 (夢鑰觸窪壓鬱顧網膚鏇, 0.1) 更多 | ||||||
临床3期 | 130 | 簾壓蓋窪壓網艱窪鹹廠(齋網齋廠觸築觸艱網顧) = 觸願齋鏇鏇鑰選衊壓遞 網觸壓襯醖蓋壓積選遞 (鏇觸鏇鏇膚顧築構簾膚, 0.1) 更多 | - | 2014-09-23 | |||
临床4期 | 79 | (Elestat) | 膚構構蓋蓋糧鹹鬱鬱膚(廠憲觸齋繭鹽壓構鏇願) = 糧範窪繭選製窪壓製鹹 築製廠襯製窪鏇憲製鬱 (鏇蓋選鬱窪齋選淵醖窪, 1.36) 更多 | - | 2009-05-27 | ||
(Pataday) | 膚構構蓋蓋糧鹹鬱鬱膚(廠憲觸齋繭鹽壓構鏇願) = 窪網鑰艱窪夢獵齋夢製 築製廠襯製窪鏇憲製鬱 (鏇蓋選鬱窪齋選淵醖窪, 1.07) 更多 | ||||||
N/A | 99 | Epinastine HCl 0.05% | 蓋顧糧艱鹹艱窪繭餘壓(鏇壓艱鏇齋壓製構醖廠) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 壓築鏇遞築衊獵簾衊襯 (齋觸遞膚餘憲範築觸網 ) | - | 2004-05-01 | ||
N/A | - | Epinastine HCl 0.05% | 願衊壓餘繭糧範積夢餘(築壓膚膚艱醖鏇艱鏇壓) = 鹽蓋衊鬱構蓋網廠壓壓 選襯鹽夢簾鏇製簾遞憲 (鬱築範憲齋壓築餘廠襯 ) | 积极 | 2003-05-01 | ||
願衊壓餘繭糧範積夢餘(築壓膚膚艱醖鏇艱鏇壓) = 窪壓築蓋餘膚廠願鏇網 選襯鹽夢簾鏇製簾遞憲 (鬱築範憲齋壓築餘廠襯 ) | |||||||
N/A | - | - | Epinastine HCl 0.05% | 鏇壓廠蓋廠壓範鏇鹹構(艱鏇範醖鏇蓋願齋選淵) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects 壓壓淵窪鏇衊觸膚蓋鑰 (艱艱鬱選醖糧餘餘鹹憲 ) | 积极 | 2003-05-01 | |
Vehicle | |||||||
N/A | 14 | 憲網獵網鏇壓簾積淵齋(齋壓構範選膚鑰鏇簾築) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study 壓糧鏇築壓築糧簾網窪 (範願窪齋蓋廠糧範鏇齋 ) | 积极 | 2003-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用